Superworth

Benitec Biopharma revenue BNTC

Sales by quarter and over the last twelve months, from 2019.

Last 12 months, to Mar 31, 2026
n/m
a quarter missing
Latest quarter, Q3 FY26
$0
Fiscal year 2024
$0
−100% on the year before

Benitec Biopharma's twelve-month revenue can't be added up yet: a quarter of its results is missing from our data.

In its latest quarter, Q3 FY26, it was $0.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2024$0−100%
FY2023$75K+3%
FY2022$73K+24%
FY2021$59Kn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q3 FY26$0n/an/a
Q2 FY26$0n/an/a
Q1 FY26$0n/an/a
Q3 FY25$0n/a$0
Q2 FY25$0n/a$0
Q1 FY25$0n/a$0
Q4 FY24$0−100%$0
Q3 FY24$0−100%$7K
Q2 FY24$0−100%$61K
Q1 FY24$0n/a$75K
Q4 FY23$7Kn/a$75K
Q3 FY23$54K+13%$68K

Against its peers

Companies in Drug Manufacturers - General nearest Benitec Biopharma's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
BNTCBenitec Biopharman/m
NATRNatures Sunshine Products$492M+7% a year
ARVNArvinas$316.7M−15% a year
PBYIPuma Biotechnology$231.2M−3% a year
IRWDIronwood Pharmaceuticals$389.3M+26% a year
ZVRAZevra Therapeutics$136.1M+119% a year
CRMDCorMedix$462.2M+281% a year
COLLCollegium Pharmaceutical$808.2M+14% a year
ABUSArbutus Biopharma$181.7M
AMPHAmphastar Pharmaceuticals$730M+1% a year
OMEROmerosn/m
Peer median$389.3M

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on Benitec Biopharma

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.